| Literature DB >> 23985166 |
Luis Pérez del Villar1, Belén Vicente, Purificación Galindo-Villardón, Andrés Castellanos, Jesús Pérez-Losada, Antonio Muro.
Abstract
Most Schistosoma mansoni experimental infections are developed in several inbred strains of Mus musculus as definitive host. In contrast, Mus spretus is unexplored in Schistosoma infection studies. Mus spretus provides a high variation of immunological phenotypes being an invaluable tool for genetic studies and gene mapping. The aim of this study is to characterize hematological and immunological responses against Schistosoma mansoni infection in Mus spretus (SPRET/EiJ strain) vs. Mus musculus (CD1 strain) mice. Nine weeks after cercarial exposure, animals were perfused and the parasite burden was assessed. The parasitological data suggests that SPRET/EiJ mice tolerate higher parasite loads compared to CD1 strain. In addition, hematological parameters measured in Mus spretus group showed a significant increase in granulocytes population in early stages of infection compared to the CD1 cohort. Meanwhile, CD1 presented higher levels of lymphocytes and IgG1 in the late stages of S. mansoni experimental infection. © L. Pérez del Villar et al., published by EDP Sciences, 2013.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23985166 PMCID: PMC3756336 DOI: 10.1051/parasite/2013027
Source DB: PubMed Journal: Parasite ISSN: 1252-607X Impact factor: 3.000
Worm recovery, eggs counts in hepatic and intestinal tissues, and granulomatous lesions of Mus spretus (SPRET/EiJ strain) and Mus musculus (CD1 strain) mice.
| Worm recovery | Egg density | ||||||
|---|---|---|---|---|---|---|---|
| Sex | Mice | Male | Female | Total | Liver | Intestine | Lesions/cm2 |
| Female | SPRET/EiJ | 21.0 (9.8)* | 31.8 (18.1)* | 52.8 (27.8)* | 11571.3 (5731.5)* | 15154.8 (8830.4)* | 44.5 (1.4) |
| CD1 | 4.8 (1.7) | 5.2 (2.0) | 10.0 (3.7) | 4185.2 (1585.3) | 2600.6 (1367.5) | 38.6 (4.7) | |
| Male | SPRET/EiJ | 18.0 (6.1) | 21.0 (7.5) | 38.3 (13.4) | 17749.3 (5048.9) | 33206.3 (14678.7) | 49.6 (2.0)* |
| CD1 | 10.2 (2.3) | 11.4 (2.4) | 21.6 (4.7) | 6693.6 (940.5) | 6440.2 (2314.5) | 35.8 (2.1) | |
All results presented as: Mean (SEM). *p < 0.05.
Figure 1.Boxplot graph displaying the levels of IgG2a (A) and IgG1 (B) along Schistosoma mansoni infection, according to sex and strain of mice. +p < 0.05.
Summary of granulocytes count in Mus spretus (SPRET/EiJ strain) and Mus musculus (CD1 strain) mice during Schistosoma mansoni infection.
| Time point | Sex | Mice | Neutrophils (103 cel./μL) | Eosinophils (103 cel./μL) | Basophils (103 cel./μL) |
|---|---|---|---|---|---|
| Healthy | Female | SPRET/EiJ | 1.89 (0.57) | 0.23 (0.13) | 0.07 (0.05) |
| CD1 | 1.15 (0.26) | 0.06 (0.02) | 0.02 (0.00) | ||
| Male | SPRET/EiJ | 3.93 (1.14)* | 0.15 (0.02) | 0.04 (0.01) | |
| CD1 | 1.05 (0.09) | 0.08 (0.02) | 0.02 (0.00) | ||
| 3rd Week | Female | SPRET/EiJ | 5.25 (0.87)* | 0.41 (0.2) | 0.07 (0.05) |
| CD1 | 1.48 (0.22) | 0.13 (0.05) | 0.04 (0.02) | ||
| Male | SPRET/EiJ | 3.36 (0.34)* | 0.14 (0.05) | 0.03(0.01) | |
| CD1 | 1.38 (0.22) | 0.03 (0.01) | 0.00 (0.00) | ||
| 6th Week | Female | SPRET/EiJ | 2.80 (0.59) | 0.08 (0.03) | 0.02 (0.01) |
| CD1 | 1.99 (0.41) | 0.05 (0.02) | 0.01 (0.00) | ||
| Male | SPRET/EiJ | 3.86 (0.29)* | 0.06 (0.02) | 0.02 (0.00) | |
| CD1 | 2.43 (0.24) | 0.04 (0.01) | 0.01 (0.00) | ||
| 9th Week | Female | SPRET/EiJ | 3.67 (0.75) | 0.19 (0.09) | 0.02 (0.01) |
| CD1 | 2.05 (0.20) | 0.10 (0.03) | 0.02 (0.01) | ||
| Male | SPRET/EiJ | 3.86 (0.63) | 0.06 (0.03) | 0.01 (0.00) | |
| CD1 | 5.21 (1.00) | 0.13 (0.02) | 0.01 (0.00) |
All results presented as: Mean (SEM). *p < 0.05.
Summary of blood parameters in Mus spretus (SPRET/EiJ strain) and Mus musculus (CD1 strain) mice during Schistosoma mansoni infection.
| Time point | Sex | Mice | White blood cells (103 cel./μL) | Lymphocytes (103 cel./μL) | Monocytes (103 cel./μL) |
|---|---|---|---|---|---|
| Healthy | Female | SPRET/EiJ | 5.6 (1.4) | 2.93 (0.65) | 0.52 (0.09) |
| CD1 | 4.95 (0.8) | 3.30 (0.60) | 0.42 (0.08) | ||
| Male | SPRET/EiJ | 6.64 (1.13) | 1.95 (0.26) | 0.57 (0.07)* | |
| CD1 | 5.11 (0.4) | 3.61 (0.32)* | 0.33 (0.02) | ||
| 3rd Week | Female | SPRET/EiJ | 13.7 (1.9)* | 6.94 (0.86)* | 0.99 (0.09)* |
| CD1 | 5.62 (0.6) | 3.53 (0.26) | 0.44 (0.07) | ||
| Male | SPRET/EiJ | 5.29 (0.37) | 3.22 (0.51)* | 0.32 (0.03) | |
| CD1 | 4.95 (0.7) | 1.43 (0.32) | 0.31 (0.03) | ||
| 6th Week | Female | SPRET/EiJ | 6.0 (0.9) | 2.55 (0.51) | 0.56 (0.03) |
| CD1 | 7.14 (1.14) | 4.18 (0.64) | 0.896 (0.18) | ||
| Male | SPRET/EiJ | 6.8 (0.6) | 2.12 (0.27) | 0.730 (0.04) | |
| CD1 | 8.14 (1.04) | 5.07 (0.78)* | 0.581 (0.11) | ||
| 9th Week | Female | SPRET/EiJ | 6.51 (1.37) | 1.92 (0.51) | 0.67 (0.10) |
| CD1 | 5.78 (0.54) | 3.16 (0.46) | 0.44 (0.03) | ||
| Male | SPRET/EiJ | 6.74 (1.74) | 2.19 (1.04) | 0.60 (0.13) | |
| CD1 | 11.24 (1.29)* | 5.15 (0.61)* | 0.71 (0.10) |
All results presented as: Mean (SEM). *p < 0.05.